The administation has seeded at least 300,000 latent TB carriers and 30,000 active cases all around the US. Children with active cases of TB WILL be showing up in schools next month. TB is about to become endemic once again in the US. Question is, does CEMI have a test in the works which outperforms the current one? That would be a big deal.
It's going to be big or small. Two top executives left. When the a Chief Science Office and CEO resign together it seems very unusual. Also, immediately replaced. Could be a Board decision but even then there is something behind that to be so sudden.
"Alere Inc. said Chief Operating Officer Namal Nawana will serve as an interim CEO while the company searches for a permanent replacement for Zwanziger, who had led the company since its inception in May 2001. He also had served as chairman from 2001 until May.
David Scott also had served as chief scientific officer since the company's inception. Jerry McAleer had served as senior vice president of research and development since July 2010 and had been a company vice president since its inception."
Big: something will come out on some testing etc that will have ramifications. I wonder if Determines poor results have bee buried or if Determine was over played. They have so many products so Determine is just one in a camels back. What broke the back?
Small: they left together for another opportunity
Food safety is an unsolved problem with an estimated 48 million foodborne illnesses occurring each year and costing over $50 billion.
PURE Bioscience is revolutionizing food safety with their heavily patented “SDC” and is positioned to become a leader in the food industry.
SDC has already been tested in several large restaurant chains and the results were significantly superior to all other methods. SDC is a powerful and extremely effective antimicrobial but it is safe to humans and has been granted the EPA’s safest product classification of a category IV.
LARGE RESTAURANT CHAINS are placing reorders that are expected to continue to increase to very sizeable numbers. PURE believes this is a 1.5 billion dollar market and SDC is far ahead of the competition.
Based on meetings with the USDA and the FDA, FOOD PROCESSORS are expected to be using SDC in 2015 to decontaminate produce and meat. SDC will also extend shelf life as well as reduce manufacturers costs. PURE believes this is billion-dollar market.
No other product can do what SDC does and do it safely.
SDC will dominate antimicrobials in hospitals, schools, homes, offices, markets, public places, cruise ships, airplanes, trains, personal products like soaps and everywhere the public gathers. Antimicrobial market for disease protection such as influenza, MRSA, etc. is another multi-billion dollar market
SDC is perfectly safe and it continues to kill dangerous pathogens for 24 hours EVEN AFTER IT DRIES.
PURE Bioscience is on the verge of delivering very large and fast growing revenues beginning this year and shares are trading between $1.10 and $1.20 with a very small market cap of $32 million.
All this information can be confirmed on YAHOO FINANCE under “PURE”
PURE is a Strong Buy and Hold
Sentiment: Strong Buy
You write as if you're on a first-name basis with the former ALR CEO. I do agree that there will be big changes at ALR. However, CEO searches take many months, as we've seen. Then, the new CEO will need time to study the company's operations. Then, if there are to be divestitures, that will make many months more. We're probably looking at up to two years before anything of significance happens at ALR.
Spurzel has his hands full cleaning up the mess left by LS, specifically as regards to failure to win timely approvals, the failure to bring new products to market, and the failure to create a DPP licensing revenue stream. The fact that CEMI doesn't have a DPP Ag/Ab or a DPP HCV product ready is particularly glaring.
Ron’s departure signifies the future divestiture of various Alere businesses...i.e. the health management groups that have not developed into the vehicles for driving "to-the-home" diagnostics. Ron had a good vision for the future of healthcare...unfortunately it wasn’t the correct one. I agree with Sono that his departure doesn’t change anything. However, I still consider Alere the primary purchaser of Chembio when the purchase of the company becomes accretive to Alere earnings.
I could not find any reference on various Alere web pages to the fact that Determine Combo is not waived. Alere's strategy seems to be to ignore that fact. Does the FDA care that Alere is pretending the product has a waiver already? Probably not.
It sure can't hurt CEMI the way I see it...as their future competitor is in disarray. Same thing CEMI went thru this past year.
Anybody's guess as to how this will impact Cemi. On the "street level" probably not much for the near and mid term......there won't be any buy outs until a new management team is in place and get their or his or her feet on the ground......it may help on the margin if the reverberations penetrate the operations and Cemi is able to take advantage of the market place....but, still the most important decisions are made by those who buy these products........will they be chilled on buying Alere???.....maybe......let's hope so.
And a big down today on low shares. People buy socks that cost more than what is being traded. Clowns on board!
I believe "accurate" is the key term. I can't remember the DPP specs. If they are close to 99% that might please Johns Hopkins. Then again it depends on what they are looking for (a lower percent for out-reach might be acceptable). For certain, Johns Hopkins and all transplant hospitals should adopt DPP HIV now to test donors right before donation time. Donors get lab tested but their was one case when someone got HIV between lab test and donation time.
It's not a huge market at all (35K live donor trans plants a year I think). But, it would be great for Chembio PR.
Excellent, Sonomaca. Thanks for link to WHO guidance on mother-to-child transmission of HIV/Syphilis. apps.who.int/iris/bitstream/10665/112858/1/9789241505888_eng.pdf?ua=1&ua=1
You have proven yourself to be as big of a Clown as that mScuba kid.
No one in their right mind would try and "rationalize" going NOWHERE FOR THE ENTIRE YEAR like CEMI has. You are an idiot.
At just 30% market penetration of 80 million Americans over the age of 50, EXAS will generate over $9.00 of earnings and be pushing $200 per share based on an ASP of $320 and 30% net margins.
And should the USPSTF recommend paying for colon cancer screening starting at age 40 where there are another 40 million Americans between the ages of 40 - 49, then the addressable market goes up by 50% for ColoGuard.
You are just too dumb to know anything about the Molecular Diagnostics market.
Goldman Sachs came aboard the EXAS "freight-train" on June 4th.
Who covers CEMI again???